

- correlation with microscopic markers of hypoxia. *Int J Radiat Oncol Biol Phys.* 2012;84:e393–e399.
23. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? *Biochim Biophys Acta.* 2009;1795:162–172.
 24. Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. *Cancer Biol Ther.* 2007;6:70–75.
 25. Taghian A, Lespinasse F, Guichard ME. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. *Int J Radiat Oncol Biol Phys.* 1991;21:1535–1540.
 26. Isoda T, Engles J, Wahl R. Time dependence of hypoxia-specific accumulation of pimonidazole in rodent breast cancers [abstract]. *J Nucl Med.* 2010;51(suppl 2):228.
 27. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using ¹⁸F-fluoromisonidazole and ⁶⁴Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. *Int J Radiat Oncol Biol Phys.* 2005;61:1493–1502.
 28. Hansen AE, Kristensen AT, Jørgensen JT, et al. ⁶⁴Cu-ATSM and ¹⁸FDG PET uptake and ⁶⁴Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. *Radiat Oncol.* 2012;7:89.
 29. Bowen SR, van der Kogel AJ, Nordmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. *Nucl Med Biol.* 2011;38:771–780.
 30. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. *Biochem Biophys Res Commun.* 2005;331:718–725.
 31. Nordmark M, Eriksen JG, GebSKI V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. *Radiother Oncol.* 2007;83:389–397.
 32. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC, Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. *Int J Radiat Oncol Biol Phys.* 2006;64:592–602.
 33. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. *J Nucl Med.* 2010;51:1167–1170.
 34. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. *Int J Radiat Oncol Biol Phys.* 2000;47:551–560.

Errata

In the article “Assessment of Tumoricidal Efficacy and Response to Treatment with ¹⁸F-FDG PET/CT After Intra-arterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor,” by Liapi et al. (*J Nucl Med.* 2011;52:225–230), there was a typographic error in one of the grants mentioned in the “Acknowledgments” section. The study was supported by NIH/NCI grant RO1 CA100883-01, not CA100882-01. The authors regret the error.

In the article “Radioimmunotherapy with ¹⁷⁷Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas,” by Forrer et al. (*J Nucl Med.* 2013;54:1045–1052), there was an error in the reported mean doses to the 20 patients. The correct whole-body dose is 0.32 mGy/MBq, and the correct absorbed dose to the red marrow is 0.36 mGy/MBq. The authors regret the error.

In Table 1 of “The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0,” by Maurer et al. (*J Nucl Med.* 2013;54:2004–2013), administered activity was incorrectly given in units of MBq/kg (mCi/kg) instead of MBq (mCi). The authors regret the error.